Understand the source comparison
SS-LUP-332 for Muscle Performance vs Exercise Mimetics: Mechanistic Differences
SS-LUP-332 is often grouped with AICAR (5-Aminoimidazole-4-carboxamide ribonucleotide) and GW501516 as an 'exercise mimetic,' but the pathways differ meaningfully. AICAR activates AMPK directly by mimicking AMP, the energy-depletion signal that tells cells to
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- SS-LUP-332 is often grouped with AICAR (5-Aminoimidazole-4-carboxamide ribonucleotide) and GW501516 as an 'exercise mimetic,' but the pathways differ meaningfully. AICAR activates AMPK directly by mimicking AMP, the energy-depletion signal that tells cells to increase glucose uptake and fatty acid oxidation. GW501516 activates PPARδ, which increases fatty acid oxidation gene expression but doesn't strongly affect mitochondrial biogenesis. SS-LUP-332 works upstream of both. It activates the ERR pathway, which then coordinates AMPK signaling, PGC-1α expression, and mitochondrial biogenesis simultaneously. The effect is more comprehensive metabolic reprogramming than either AICAR or GW501516 alone.
- The performance phenotype produced by SS-LUP-332 for muscle performance in research models includes increased time-to-exhaustion in forced swim tests (70% longer than vehicle-treated controls), improved lactate clearance during high-intensity intervals, and maintained muscle glycogen stores during prolonged submaximal exercise. These aren't effects you see with anabolic compounds. Growth hormone secretagogues like Ipamorelin or CJC 1295 increase lean mass and strength but don't improve oxidative capacity. Myostatin inhibitors increase muscle size but don't enhance mitochondrial function. SS-LUP-332's mechanism is orthogonal to anabolic signaling entirely. It's metabolic adaptation without hypertrophy.
- One mechanistic nuance: SS-LUP-332 doesn't require exercise to produce its metabolic effects, but the magnitude of adaptation is greater when combined with training stimulus. Rodent studies pairing SS-LUP-332 administration with voluntary wheel running showed additive improvements. The compound produced a 50% endurance increase on its own, and exercise alone produced 40%, but combining both yielded 110–120% improvement over sedentary controls. The ERR pathway and exercise-induced signaling converge on the same transcriptional targets (PGC-1α, mitochondrial genes), so activating both simultaneously amplifies the response beyond either alone.
- Our synthesis process for SS-LUP-332 for muscle performance prioritizes batch consistency because even 5–10% potency variation changes the effective dose required to reach ERR receptor saturation. Every batch undergoes HPLC verification to confirm purity exceeds 98% before we release it for research applications. Researchers studying metabolic remodeling need reproducible results across experiments. Variability in compound purity introduces confounding variables that obscure whether observed effects are dose-related or artifact.